<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005092</url>
  </required_header>
  <id_info>
    <org_study_id>DM98-283</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-98283</secondary_id>
    <secondary_id>NCI-G00-1742</secondary_id>
    <secondary_id>CDR0000067734</secondary_id>
    <nct_id>NCT00005092</nct_id>
  </id_info>
  <brief_title>Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were
      destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the
      transplanted cells are rejected by the body's normal tissues. Transplanting donated cells
      that have been treated with psoralen may prevent this from happening.

      PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and
      psoralen-treated donor cells in treating patients who are undergoing peripheral stem cell
      transplantation for hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of T-cells photochemically treated with
      psoralen and ultraviolet A given with peripheral stem cell transplantation in patients with
      hematologic malignancies or bone marrow failure myelodysplastic syndrome. II. Assess the
      toxicity of this treatment in these patients. III. Evaluate this regimen in terms of
      prevention of graft versus host disease and control of malignancy in these patients.

      OUTLINE: This is a dose escalation, multicenter study of T-cells photochemically treated with
      psoralen and ultraviolet A. Patients receive thiotepa IV over 2 hours on day 1,
      cyclophosphamide IV over 2 hours on days 2 and 3, and whole body radiotherapy on days 5-8.
      Patients undergo preserved stem cell or bone marrow allogeneic transplant plus psoralen
      treated T-cell allogeneic transplant on day 9. Cohorts of 3-6 patients receive escalating
      doses of photochemically treated T-cells until the maximum tolerated dose (MTD) is
      determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients
      experience dose limiting toxicities. Patients are followed for 100 days.

      PROJECTED ACCRUAL: A maximum of 37 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of T-cells photochemically treated with psoralen and ultraviolet A</measure>
    <time_frame>100 days</time_frame>
    <description>MTD defined as dose preceding that at which at least 2 of 3 patients experience dose limiting toxicities. Patients followed for 100 days.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Chemo, RT + PSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>IV over 2 hours on days 2 and 3</description>
    <arm_group_label>Chemo, RT + PSCT</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psoralen</intervention_name>
    <description>Psoralen treated T-cell allogeneic transplant on day 9</description>
    <arm_group_label>Chemo, RT + PSCT</arm_group_label>
    <other_name>Methoxsalen</other_name>
    <other_name>8-methoxypsoralen</other_name>
    <other_name>UVADEX</other_name>
    <other_name>Oxsoralen-Ultra</other_name>
    <other_name>Oxsoralen</other_name>
    <other_name>8-MOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>IV over 2 hours on day 1</description>
    <arm_group_label>Chemo, RT + PSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic bone marrow transplantation</intervention_name>
    <description>Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9</description>
    <arm_group_label>Chemo, RT + PSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In vitro-treated peripheral blood stem cell transplantation (PBSCT)</intervention_name>
    <description>Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9</description>
    <arm_group_label>Chemo, RT + PSCT</arm_group_label>
    <other_name>PBSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy (RT)</intervention_name>
    <description>Whole body radiotherapy on days 5-8.</description>
    <arm_group_label>Chemo, RT + PSCT</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Hematologic malignancy, including acute myeloid or lymphoid
        leukemia of any FAB subtype, not in remission with chemotherapy or requiring bone marrow
        transplant OR Chronic myeloid leukemia, advanced beyond first chronic phase OR
        Myelodysplasia, including secondary to prior chemotherapy, with: Granulocyte count less
        than 500/mm3 OR Platelet count less than 50,000/mm3 OR High risk cytogenetic abnormalities
        such as +8, -7, -5, or 11q23 OR Intermediate or high grade lymphoma without response to
        initial therapy or in relapse OR Multiple myeloma without response to initial therapy or in
        relapse OR Stage IV low grade lymphoma or chronic lymphocytic leukemia not achieving
        remission with 2 regimens No aplastic anemia Related haploidentical donor (1-3 HLA-A, B,
        and/or DR mismatch) for collection of stem cells and whole blood T-cells required

        PATIENT CHARACTERISTICS: Age: 6 months to 49 years Performance status: ECOG 0-2 Life
        expectancy: Greater than 12 weeks Hematopoietic: See Disease Characteristics Hepatic:
        Bilirubin less than 1.5 mg/dL SGPT less than 3 times upper limit of normal Renal:
        Creatinine less than 1.5 mg/dL Cardiovascular: Left ventricular ejection fraction at least
        45% No symptoms or active treatment of left ventricular failure Pulmonary: Corrected DLCO
        at least 50% Other: No acute viral, bacterial, or fungal infection No prior transfusion
        associated graft versus host disease No other medical condition that would preclude study
        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective
        contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior immunotherapy or
        interferon alfa and recovered No prior autologous or allogeneic progenitor cell transplant
        Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy and
        recovered Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior
        radiotherapy and recovered Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Gajewski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Barnard Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>April 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>adult acute monoblastic leukemia and acute monocytic leukemia (M5)</keyword>
  <keyword>childhood acute monoblastic leukemia and acute monocytic leukemia (M5)</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
  <keyword>L1 childhood acute lymphoblastic leukemia</keyword>
  <keyword>L2 childhood acute lymphoblastic leukemia</keyword>
  <keyword>L3 childhood acute lymphoblastic leukemia</keyword>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B childhood acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia</keyword>
  <keyword>L1 adult acute lymphoblastic leukemia</keyword>
  <keyword>L2 adult acute lymphoblastic leukemia</keyword>
  <keyword>L3 adult acute lymphoblastic leukemia</keyword>
  <keyword>T-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>B-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B adult acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa positive adult acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa positive, pre-B adult acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa negative adult acute lymphoblastic leukemia</keyword>
  <keyword>TdT positive adult acute lymphoblastic leukemia</keyword>
  <keyword>TdT negative adult acute lymphoblastic leukemia</keyword>
  <keyword>TdT negative childhood acute lymphoblastic leukemia</keyword>
  <keyword>TdT positive childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute eosinophilic leukemia</keyword>
  <keyword>childhood acute basophilic leukemia</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>childhood large cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Amotosalen</mesh_term>
    <mesh_term>Furocoumarins</mesh_term>
    <mesh_term>Ficusin</mesh_term>
    <mesh_term>Methoxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

